 group
(Table II).
8. Neurologically asymptomatic patients deemed high
risk for CEA, TCAR, and transfemoral CAS should be
considered for primary medical management. Intervention can be considered in these patients only
with evidence that perioperative morbidity and mortality is less than 3%. CAS should not be performed
in these patients except as part of an ongoing clinical
trial.
9. There are insufÔ¨Åcient data to recommend transfemoral CAS as primary therapy